CXCR4 and lip and oral cavity carcinoma: Instead, Akt pathway activation in MRE11 overexpressing oral cancer was mediated by the C-X-C chemokine receptor type 4 (CXCR4), suggesting CXCR4 inhibitors as a potential treatment option specifically for this tumor entity [82].